October 17 – 19 2017 | Boston, MA

Hyatt Regency Boston

Discover & Validate Novel Predictive Biomarkers

Improve Your Selection of Patient Responders

Effectively Deliver Diagnostic-Enabled Therapies to Market

Back for the 8th year, World CDx Boston remains the only forum dedicated to helping large pharma and biotech drug developers turn predictive biomarkers into clinically validated companion diagnostic assays for their precision medicine candidates.

Bringing together thought leaders and pioneers in the biomarker, CDx and precision medicine fields, World CDx Boston provides a much needed platform for candid conversations on how to define, adopt and implement a CDx strategy to ensure your drug candidates are regulatory compliant, achieve reimbursement and gain market share.

By better selecting and stratifying the responder patient populations for your drug candidates, World CDx Boston facilitates discussion on how to not only de-risk, but accelerate the demonstration of efficacy and clinical value of your targeted therapeutics: for both oncology and non-oncology indications. World CDx offers solution-led thinking for key industry challenges including regulatory approval, pricing and reimbursement coverage and the health economics behind market access hurdles to achieve global commercialization of drug-CDx combinations.

For  exclusive updates and to be the first to receive our agenda, please register your interest here.

“World CDx was a fantastic event both in terms of the science and the networking opportunities."

- Oscar Puig, Biomarker Leader, Oncology, Roche

Media Partner